BiotechTube

dexmedetomidine + propofol

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

MRI Sedation

Conditions

MRI Sedation

Trial Timeline

Feb 18, 2020 → Nov 30, 2021

NCT ID
NCT04237792

About dexmedetomidine + propofol

dexmedetomidine + propofol is a approved stage product being developed by Pfizer for MRI Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT04237792. Target conditions include MRI Sedation.

What happened to similar drugs?

8 of 20 similar drugs in MRI Sedation were approved

Approved (8) Terminated (2) Active (12)
✅Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
✅fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
✅Dexmedetomidine load + Ketamine load + Midazolam load + Fentanyl load + Dexmedetomidine maintenance + Ketamine maintenance + Midazolam demand + Fentanyl demand + Benadryl demandPfizerApproved
✅Dexmedetomidine + PropofolPfizerApproved
✅DexmedetomidinePfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04237792ApprovedCompleted
NCT00538616Phase 1/2Completed
NCT00318955ApprovedCompleted

Competing Products

20 competing products in MRI Sedation

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
40
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
35
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
43
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
38
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
32
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
29
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
39
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
29
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
25
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
35
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
34